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Background: The absence of markers for ante-mortem diagnosis of progressive
supranuclear palsy (PSP), results in this disorder being commonly mistaken for
other conditions, such as idiopathic Parkinson’s disease (IPD). Such mistakes occur
particularly in the initial stages, when “plus syndrome” has not yet clinically emerged.
Objective: To investigate the global brain volume and tissue loss in patients with PSP
relative to patients with IPD and healthy controls and correlations between clinical
parameters and magnetic resonance imaging (MRI)-derived brain volume estimates.
Methods: T1-weighted images were obtained from three groups of Chilean Latin
American adults: 21 patients with IPD, 18 patients with PSP and 14 healthy controls. We
used Structural Imaging Evaluation with Normalization of Atrophy (SIENAX) to assess
white matter, gray matter and whole-brain volumes (normalized to cranial volume).
Imaging data were used to analyze putative correlations with the clinical status of PSP
and IPD patients using the Unified Parkinson’s Disease Rating Scale Part III (UPDRS III),
Hoehn and Yahr (H&Y), the Clinical Global Impression for Disease Severity Scale (CGI-S)
and the Frontal Assessment Battery (FAB).
Results: PSP patients had significantly lower whole brain volume than both IPD patients
and controls. Whole brain volume reduction in PSP patients was primarily attributable to
gray matter volume reduction. We found a significant correlation between brain volume
reduction and clinical status in the PSP group.
Conclusions: At the group level, the whole brain and gray matter volumes differentiated
patients with PSP from patients with IPD. There was also significant clinical-imaging
correlations with motor disturbances in PSP.
Keywords: progressive supranuclear palsy, idiopathic Parkinson’s disease, whole brain atrophy state, SIENA,
SIENAX
INTRODUCTION
Progressive supranuclear palsy (PSP) is the second most common neurodegenerative
movement disorder after idiopathic Parkinson’s disease (IPD). PSP is a debilitating
disease characterized by early postural instability, ophthalmoplegia, pseudobulbar palsy,
dysarthria, axial rigidity, frontal lobe dysfunction and dementia. PSP exhibits inexorable
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progression, with a median survival time of between 5 and 10
years (Bower et al., 1997). No disease-modifying treatments
have been developed since Steele et al. (1964) described
PSP in 1963. The definitive diagnosis of PSP is based on
the presence of intracellular deposits of neurofibrillary
tangle inclusions composed of abnormally phosphorylated
microtubules associated with protein-tau (Verny et al.,
1996). It is suspected that abnormal inclusions are causally
related to cell death because widespread neuronal loss
is generally observed in those areas with tau pathology
(Williams et al., 2007).
In contrast, IPD is a synucleinopathy restricted to the
substantia nigra and other subcortical brain nuclei, and it is
characterized by neural depletion, replacement gliosis and
intraneural formation of Lewy bodies. The main clinical
manifestations are resting tremor, rigidity, impaired postural
reflexes and sustained response to levodopa (L-DOPA)
treatment.
Despite these differences, both disorders share some common
clinical features, such as akinetic rigidity, making the diagnosis,
which is initially based on clinical presentation only, rather
difficult, especially in early stages. For the approach to the
diagnosis and differential diagnosis of parkinsonian syndromes
no quantitative magnetic resonance imaging (qMRI) technique
is specifically recommended for routine use in clinical practice
(Politis, 2014).
In vivo qMRI studies have largely used voxel based
morphometry (VBM) to study tissue loss independently of
prior (regional) assumptions throughout brains. A recent meta-
analysis of gray matter loss in IPD suggests that these patients
have reduced volume in the inferior frontal gyrus and precentral
gyrus (Shao et al., 2014), but another meta-analysis of gray
matter loss reports that IPD does not show any significant
distinguished area of atrophy (Yu et al., 2015). By contrary,
in PSP, qMRI studies have been more consistent to reflect
the ongoing neuronal loss in the lateral orbitofrontal and
dorsolateral prefrontal cortices (Brenneis et al., 2004; Cordato
et al., 2005; Padovani et al., 2006) and in the thalamus and
caudate nucleus (Price et al., 2004; Boxer et al., 2006). Some
VBM studies have reported being able to differentiate PSP from
IPD at the group level (Price et al., 2004). However, there is
no clinical application for VBM. This technique only allows
between groups analyses or within group correlations to explore
tissue loss independently of prior assumptions throughout the
brains.
Here, we are interested in a qMRI technique suitable to be
applied at the individual level with a potential clinical utility
in the differential diagnosis in parkinsonian syndromes. In
this study, we have chosen the Structural Imaging Evaluation
with Normalization of Atrophy (SIENAX). SIENAX is an MRI-
based algorithm that quantifies loss of brain tissue volume
by normalizing the brain volume to the cranial volume
(a proxy for premorbid brain volume). The method is fully
automated with 0.5–1% brain volume accuracy for single
time point (cross-sectional) designs (Smith et al., 2001, 2004).
SIENA will be used in patients with IPD and PSP and
in healthy controls. Our hypothesis is that IPD at early
stages may not have atrophy outside the substantia nigra
and that PSP does have widespread tissue loss. Thus global
measurement of brain volume and tissue type-specific volumes
(i.e., gray and white matter volumes) could be a useful
tool to improve the differentiation between IPD and PSP
patients.
MATERIALS AND METHODS
This project was approved by the local Research Ethics
Committees of San Juan de Dios Hospital, Santiago, Chile.
Written informed consent was provided by all of the subjects
prior to participation in the study.
Subjects and Clinical Assessments
Three groups of Chilean Latin American adults, including PSP
patients (n = 18), IPD patients (n = 21) and healthy controls
(n = 14), were selected. The patients were recruited from
the Movement Disorders Clinic at Hospital San Juan de Dios,
Santiago, Chile. Internationally established operational criteria
were used to assess the diagnoses of PSP and IPD (Hughes
et al., 1992; Litvan et al., 2003). The clinical characteristics
and demographics of each group are shown in Table 1. Every
patient was examined by the same clinician (CG) within 1 week
of the MRI scan acquisition. None of the patient was treated
with cognition enhancing agents. Fourteen IPD patients had
the tremor dominant phenotype and seven had the postural
instability gait disorder phenotype. All IPD subjects were treated
with dopaminergic medication and were examined first on one
morning in their ‘‘best on’’ state. Of the 18 PSP patients, 16 had
the typical features of classic PSP (Richardson’s syndrome) and
two had an atypical profile with tremor and moderate L-DOPA
responsiveness (PSP-Parkinsonism variant).
Clinical assessments of both disease groups included the
following instruments:
– Hoehn and Yahr Scale (H&Y). This scale was originally
designed for the assessment of the general severity of IPD
patients. However, it is also widely used for PSP. This simple
tool estimates both the transition from unilateral to bilateral
motor involvement and the impairment of balance and gait
(Hoehn and Yahr, 2001).
– Unified Parkinson’s disease Rating Scale Part III (UPDRS III).
This scale is also commonly used in PSP evaluations. Factor
analysis has revealed that some of the items of the UPDRS III
can be applied in assessing both conditions regarding axial and
limb bradykinesia, tremor and rigidity, and face and speech
disturbances (Cubo et al., 2000).
– Clinical Global Impression for Disease Severity (CGI-S). This
is a short scale that relies upon the clinician’s appraisal of the
severity of the disorder. It rates patient’s status on a 1–7 scale,
where 1 = ‘‘normal, not at all ill’’, and 7 = ‘‘extremely ill’’.
It has been suggested that this scale is particularly influenced
by motor signs, general disability and cognitive impairment in
IPD (Martínez-Martín et al., 2006).
– The Frontal Assessment Battery (FAB). This scale was
designed to detect the dysexecutive syndrome at the bedside of
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TABLE 1 | Demographics, clinical and volumetric data in idiopathic Parkinson’s disease (IPD), progressive supranuclear palsy (PSP) and control groups.
IPD group PSP group Control group Group comparisons Signifcant pair wise
n = 21 n = 18 n = 14 comparisons
Age at examination (years ± SD) 62.6 ± 11.1 67.7 ± 9.0 65.2 ± 6.4 F = 1.9; df = 2; p = 0.14
Gender Female (n): Male (n) 12:9 9:9 9:5 χ2 = 0.65; df = 1; p = 0.71
Disease duration (years ± SD) 3.3 ± 3.5 2.8 ± 2.1 – p = 0.26; t = 0.54; df = 37; F = 5.36
UPDRS III (mean ± SD) 23.0 ± 12.0 44.0 ± 16.0 – p < 0.001; z = −3.75
H & Y (mean ± SD) 1.9 ± 0.7 2.8 ± 0.9 – p < 0.001; z = −3.25
CGI-S (mean ± SD) 3.5 ± 0.7 4.5 ± 0.7 – p < 0.001; z = −3.64
FAB (mean ± SD) 14.5 ± 3.3 10.8 ± 4.8 – p = 0.015; z = −2.42
Normalized brain volumes
Whole brain volume (ml ± SD) 1547.0 ± 67.0 1470.0 ± 104.0 1548.0 ± 76.0 F = 5.08; df = 2; p = 0.01 PSP vs.Controls = 0.031
PSP vs. IPD = 0.016
Gray matter volume (ml ± SD) 775.0 ± 41.0 723.0 ± 85.0 757.0 ± 41.0 F = 5.5; df = 2; p = 0.007 PSP vs. Controls = 0.01
PSP vs. IPD = 0.031
White matter volume (ml ± SD) 772.0 ± 40.0 731.0 ± 79.0 757.0 ± 40.0 F = 2.6; df = 2; p = 0.08
patients with extrapyramidal disorders, including PSP (Dubois
et al., 2000). It consists of six sub-tests intended to explore
individual executive functions: conceptualization, mental
flexibility, motor programming, sensitivity to interference of
inhibitory control and environmental autonomy. The scale has
a maximum of 18 points, with higher scores indicating better
performance.
MRI Acquisition
MRI images were acquired on a 3.0 T Philips Medical System.
Axial T1-weighted images, covering the whole brain, were
obtained using a 3D inversion recovery prepared spoiled
gradient echo (IR-SPGR) sequence. The following parameters
were used: repetition time (TR) of 8.1 ms; echo time (TE)
of 3.7 ms; inversion time (TI) of 450 ms; voxel size of
0.699 × 0.699 × 1 mm; excitation flip angle of 8o; matrix
size of 248 × 226; field of view (FOV) of 24 cm; 198 axial
1-mm slices. MRI scans of every patient were assessed by an
experienced neuroradiologist (GG) to exclude gross anatomical
abnormalities.
Imaging Processing
All of the data were made anonymous by removing any
references to the patient’s name from the image headers and
replacing these data with a unique ID. Whole brain volume
and brain tissue volumes were estimated using SIENAX (Smith
et al., 2001, 2002, 2004). Briefly, SIENAX extracts brain and
skull images from the acquired MRI data. The brain image is
then affine-registered to Montreal Neurological Institute (MNI)
152 space, using the skull image to determine the registration
scaling. The registration scaling is then used to obtain a
volumetric scaling factor, which is employed to normalize tissue
volume estimates. Segmentation with partial volume estimation
is subsequently performed to calculate total volume of brain
tissue, including separate estimates of volumes of graymatter and
white matter (Smith et al., 2004).
Statistical Analyses
Analyses of the clinical data and clinical-imaging correlations
were performed using the Statistical Package for Social Sciences
(SPSS, Inc., Chicago, IL, USA, version 22). The results are
presented as the mean ± standard deviation (SD). In all cases, a
two-sided p value of <0.05 was considered as significant. Visual
inspection of the data, using histograms and QQ-plots, was
undertaken to check for violations of the assumption of normal
distribution. Levene’s test of equal variances was used to verify
the assumption of homogeneity of variances. Based on these
assessments, parametric or non-parametric statistical tests were
then used, as appropriate. Disease duration was compared using
a two-tailed t-test. Disease severity and cognitive estimations,
which were not distributed normally, were assessed using the
Mann-Whitney test. The chi-square test for homogeneity was
used to compare the distribution of men and women across
groups. The associations between MRI-derived measurements
and clinical scores were assessed with bivariate correlations.
One way analysis of variance (ANOVA) was performed for
normally distributed data (age at examination and MRI-derived
measures). Tukey’s test was used to control for multiple
comparisons.
RESULTS
Demographics, Clinical and MRI Variables
The PSP and IPD patients exhibited clinical features typical
for their respective diagnoses (Table 1). All 18 PSP cases
had progressive symmetric parkinsonism accompanied by
postural instability, and 14 had supranuclear ophthalmoplegia.
All 21 IPD patients had L-DOPA-responsive akinetic-rigid
syndrome. There were no significant differences in age or
sex between the groups. The IPD patients had longer disease
durations than the PSP patients, while the PSP patients showed
greater impairment in the UPDRS III, H&Y, CGI-S and FAB
assessments.
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Normalized Brain Tissue Volumes (Table 1,
Figure 1)
The mean whole-brain volume in PSP was significantly lower,
compared to the IPD group (p= 0.016). The gray matter volume
FIGURE 1 | Normalized brain tissue volumes in controls, idiopathic
Parkinson’s disease (IPD) and progressive supranuclear palsy (PSP):
(A) Whole brain volume; (B) Gray matter volume; (C) White matter
volume.
in PSP was also significantly lower than in IPD (p = 0.031). The
white matter volume did not differ among the study groups. The
IPD patients did not differ from the controls in any of these
parameters.
Exploratory Correlations Between Clinical
Evaluations and Brain Tissue Volumes
(Table 2, Figure 2)
Large (r > 0.5) and significant clinical-imaging associations
were identified in PSP between the whole-brain volume and the
UPDRS III (r=−0.645; p= 0.004), H&Y (r=−0.660; p= 0.002)
and CGI-S scales (r = −0.650; p = 0.003). Additionally, the
PSP patients exhibited significant correlations between gray
matter volume and UPDRS III (r = −0.510; p = 0.030), H&Y
(r = −0.660; p = 0.003), and CGI-S scores (r = −0.610;
p = 0.007). In PSP, white matter volume was correlated with
the UPDRS III (r = −0.55; p = 0.017) and CGI-S (r = −0.65;
p= 0.003).
No significant correlations were found between whole-brain,
gray and white matter volumes with clinical parameters in IPD
(Table 2). In both disease groups, neither disease duration nor
FAB was correlated with any MRI-derived measurements.
DISCUSSION
The aim of this study was to explore global brain volume
loss in patients with PSP compared to patients with IPD and
healthy controls and to evaluate the correlations between clinical
parameters and MRI-derived brain volume estimation. Our
results showed that patients with PSP had reduced total brain
volumes, compared to both IPD patients and controls. Volume
TABLE 2 | Correlations between normalized brain volumes and clinical
scores in PSP and IPD.
Group PSP IPD
r p R p
Gray matter
UPDRS IIIa −0.510 0.030 −0.39 0.08
H & Yb −0.660 0.003 −0.30 0.17
CGI-Sc −0.610 0.007 −0.18 0.41
FABd 0.480 0.090 0.27 0.23
Disease duration −0.340 0.100 0.12 0.57
White matter
UPDRS IIIa −0.550 0.017 0.14 0.54
H & Yb −0.420 0.080 0.11 0.62
CGI-Sc −0.650 0.030 −0.20 0.91
FABd 0.360 0.200 0.14 0.54
Disease duration 0.060 0.800 0.11 0.60
Whole brain volume
UPDRS IIIa −0.645 0.004 −0.12 0.60
H & Yb −0.660 0.002 −0.12 0.60
CGI-Sc −0.650 0.003 −0.13 0.57
FABd 0.480 0.080 0.39 0.08
Disease duration −0.290 0.240 0.14 0.53
Bold text indicates significant correlations. aUnified Parkinson’s Disease Rating
Scale Part III; bHoehn & Yahr Scale; cClinical Global Impression for Disease
Severity; dThe Frontal Assessment Battery.
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FIGURE 2 | Correlations between normalized whole brain and gray matter volumes with clinical scores in PSP patients: (A) Whole brain volume and
Unified Parkinsons Disease Rating Scale Part III (UPDRS III); (B) Whole brain volume and Hoehn and Yahr (H&Y); (C) Whole brain volume and Clinical
Global Impression for Disease Severity (CGI-S); (D) Gray matter volume and UPDRS III; (E) Gray matter volume and H&Y; (F) Gray matter volume and
CGI-S.
loss was mainly due to reductions in gray matter. Furthermore,
these changes were significantly related to the clinical findings in
PSP. These results suggested that whole-brain quantitative MRI
studies could be helpful in differentiating these patients.
Patients with IPD did not show global-brain atrophy.
This could be due to a genuine lack of neuronal loss
in the early and middle stage, or it could simply reflect
that the magnitude of atrophy is not detectable when
quantified in vivo using this qMRI technique. Furthermore,
neither whole brain volume nor gray matter volume
showed any association with clinical deterioration in
the IPD group in our study. There have been two
previous works using SIENAX in IPD patients, and our
results are consistent with these studies as no brain
volume changes were found when compared with healthy
controls (Tessa et al., 2008; Dalaker et al., 2009). Thus,
the mean global brain volume in IPD supports the
idea that motor deficits in L-DOPA-responsive IPD
patients are related predominantly to localized loss
of selective dopaminergic neurons in the substantia
nigra.
Conversely, the results in the PSP group are according to
the pathological data and with previous studies using qMRI
techniques. Gray matter and whole-brain volume loss in PSP
were correlated with motor disability, as quantified using the
UPDRS III, H&Y and CGI-S. Previous studies have reported
that UPSRS III score was correlated with atrophy in the caudate
and motor cingulate cortices (Cordato et al., 2005). Our qMRI
findings were also consistent with studies in PSP patients in
which degeneration in both subcortical and cortical sites was
correlated with clinical disability (Cordato et al., 2005; Padovani
et al., 2006; Tessa et al., 2008; Lagarde et al., 2013).
Patients with PSP scored lower on the FAB test. However,
FAB scores were not significantly correlated with gray matter
loss. Previous studies have found correlations between FAB
scores and localized changes in the frontal lobe, orbitofrontal
cortex, midbrain and cerebellum (Cordato et al., 2005;
Giordano et al., 2013). Others have found no significant
correlations between localized gray matter reductions and
cognitive measurements suggesting that reductions are
more related to global cortical reductions. Using VBM,
Lagarde et al. (2013) recently reported that PSP patients,
compared to healthy controls, showed significantly lower
gray matter volumes in the left inferior temporal gyrus,
right precentral gyrus, right central gyrus, middle temporal
gyrus and the anterior nucleus of the right thalamus.
However, none of these areas showed a correlation with
FAB or with other neuropsychological evaluations, such as
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the Mattis Dementia Rating Scale (MDRS) and the Mini-
Mental State Examination (MMSE). These authors suggested
that widespread atrophy of subcortical and cortical gray
matter might have prevented them from detecting significant
correlations.
In relation with other qMRI techniques, SIENAX estimates
global tissue measures and is suitable to be applied at the
individual level. This may provide a potential utility on the
clinical ground, but it is not suitable for detecting localized
gray matter atrophy. Regional-specific method (e.g., VBM)
have different purposes. VBM has largely been used in an
unbiased fashion in these disorders and many sites of neuronal
vulnerability have been reported in IPD and PSP. These findings
are useful for generating biological hypotheses or suggesting
regions of interest for clinical and radiological works.
We think that global tissue-specific measures (e.g., SIENAX)
and regional-specific method (f.e VBM) are complementary
approaches in neurodegeneration.
A problem with using brain volume as a disease outcome
is that it may not reflect physiologic or synaptic health.
Furthermore, we do not know if the loss of brain volume
might be influenced by causes that are common in people with
chronic brain disorders, but only indirectly related to the disease
itself, such as minor head trauma, nutritional deficiency or
dehydration. Although, these sources of variance are certainly
less than those for the clinical measure. Given the actual state of
the art in neuroimaging, SIENAX may be among the simplest
MRI tools, but complex methodologies do not necessarily
lead to robust and coherent results. SIENAX offers several
advantages over other quantitative MRI techniques, including
high reproducibility of results and the capability to provide
a robust measurement of the global changes associated with
disease conditions. Moreover, a particular advantage of SIENAX
is its relative insensitivity to differences in scanning parameters,
making this tool suitable for multicenter studies (Smith et al.,
2004).
Although we presented a relatively small number of patients
in each group, our findings suggested that SIENAX can be used
to quantify in vivo brain volume loss in IPD and PSP at the group
level. Before the technique can be used diagnostically; however,
a greater number of patients and longer prospective follow-up
are needed to establish discriminatory cut-off points of these
measurements and to estimate sensitivity, specificity and positive
predictive values.
KEY CONCEPTS
– SIENAX is an MRI-based algorithm that quantifies brain
tissue volume by normalizing the brain volume to the cranial
volume. SIENAX extracts the brain and skull images from
the acquired MRI data. Segmentation with partial volume
estimation is subsequently performed to calculate total volume
of brain tissue, including separate estimates of volumes of gray
matter and white matter.
– PSP is the second most common neurodegenerative
movement disorder after IPD. PSP is a debilitating disease
characterized by early postural instability, ophthalmoplegia,
pseudobulbar palsy, dysarthria, axial rigidity, frontal
lobe dysfunction and dementia. PSP exhibits inexorable
progression, with a median survival time of between 5 and 10
years.
– PSP and PD share some common clinical features, such as
akinetic rigidity, making the diagnosis rather difficult which
is initially based on clinical presentation only, especially in
the early stages. Some imaging studies have reported being
able to differentiate PSP from IPD, although standard MRI
assessment of images is rather insensitive for the estimation
of neurodegeneration.
– At the group level, whole brain and gray matter
volumes differentiated patients with PSP from patients
with IPD.
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